Acquired lecithin:cholesterol acyltransferase deficiency as a major factor in lowering plasma HDL levels in chronic kidney disease
Journal of Internal Medicine2014Vol. 277(5), pp. 552–561
Citations Over TimeTop 10% of 2014 papers
Laura Calabresi, Sara Simonelli, Paola Conca, G Busnach, Mara Cabibbe, Loreto Gesualdo, Maddalena Gigante, Silvana Penco, Fabrizio Veglia, Guido Franceschini
Abstract
Acquired LCAT deficiency is a major cause of low plasma HDL levels in patients with CKD, thus LCAT is an attractive target for therapeutic intervention to reverse dyslipidaemia, and possibly lower the cardiovascular disease risk in these patients.
Related Papers
- → Lipoprotein Heterogeneity and its Effect on Apolipoprotein Assays(1990)11 cited
- → Does lipoprotein-X (LP-X) act as a substrate for the lecithin: Cholesterol acyltransferase (LCAT)?(1973)29 cited
- → Apolipoprotein A-1 and apolipoprotein B containing lipoprotein particles in coronary patients treated with extracorporal low density lipoprotein precipitation (HELP)(1992)9 cited
- → Lipoprotein Heterogeneity and its Effect on Apolipoprotein Assays(1990)7 cited
- → Clinical significance of apolipoprotein B containing lipoprotein particles(1990)